Atlas Trials

Efficacy and Safety of Roflumilast Foam 0.3% in Trial Participants With Seborrheic Dermatitis

Clinical trial NCT07683806 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07683806
Sponsor
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Status
NOT_YET_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Seborrheic Dermatitis
Start date
2026-08-24
Primary completion
2027-06-30
Enrollment
309

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.